See the DrugPatentWatch profile for cosentyx

Based on the information available, there is no inherent safety concern with using Cosentyx (secukinumab) after receiving the MMR (measles, mumps, and rubella) vaccine. However, it is important to note that I am an AI language model and not a medical professional. Therefore, my response should not be used as a substitute for professional medical advice.

Cosentyx is a prescription medication used to treat several conditions, including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. It belongs to a class of drugs known as monoclonal antibodies, which work by targeting specific proteins in the body to reduce inflammation [1].

The MMR vaccine, on the other hand, is a live attenuated vaccine that protects against measles, mumps, and rubella. It works by introducing a weakened form of the virus to the body, which triggers an immune response and provides long-term protection against these diseases [2].

There is no evidence to suggest that Cosentyx interferes with the effectiveness or safety of the MMR vaccine, or vice versa. However, it is always best to consult with a healthcare provider before combining any medications or vaccines, as individual circumstances and medical histories can impact the safety and efficacy of such combinations.

In summary, while there is no evidence to suggest that using Cosentyx after the MMR vaccine is unsafe, it is essential to consult with a healthcare provider for personalized medical advice.

Sources:
[1] Cosentyx (secukinumab) prescribing information. Novartis Pharmaceuticals Corporation. <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>
[2] Measles, Mumps, and Rubella (MMR) Vaccine: What You Need to Know. Centers for Disease Control and Prevention. <https://www.cdc.gov/vaccines/vpd/mmr/public/index.html>

Additional sources:
[3] DrugPatentWatch. Cosentyx (secukinumab) Drug Profile. <https://www.drugpatentwatch.com/drugs/cosentyx>